United States Pharmacopeia | Strategic Alliance Partners

Raymond Lorenz, PharmD, BCPP, discusses the role of pharmacists in bridging laboratory results and clinical practice, highlighting ongoing efforts to establish pharmacogenomic testing standards and foster multidisciplinary collaboration for broader clinical impact.

The workshop addressed trends, initiatives, and regulations for quality compounding.

Christine Formea, PharmD, MHI, BCPS, FCCP, FASHP, discusses the need for standardized pharmacogenomics education in pharmacy, highlighting opportunities for collaboration, professional growth, and integration of key competencies across curricula to advance the profession.

Blaine Groat, PharmD, discusses the evolution of US Pharmacopeia (USP)'s drug standards, highlighting new compounding guidelines, as well as USP’s commitment to pharmacogenomics and upcoming opportunities for experts to contribute to personalized medicine standards.

Stephanie Y. Crawford, PhD, MPH, highlights the expanded roles of pharmacists in clinical and non-clinical settings and their increased role in patient care, sharing personal experiences where pharmacists have been instrumental in supporting her family's health needs.

Sara Rogers, PharmD, discusses the formation and goals of the Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) initiative, which seeks to standardize pharmacogenomic practices and improve clinical decision-making by establishing consensus across all stakeholders.

Ryan Nelson, PharmD, discusses the STRIPE Annual Meeting and Consensus Workshop’s focus on unifying pharmacogenetic guidelines across major organizations, such as the FDA, European Medicines Agency, Clinical Pharmacogenetics Implementation Consortium, and National Comprehensive Cancer Network.

Damage to a Baxter manufacturing plant in the aftermath of Hurricane Helene has led to significant IV fluid shortages throughout the country.

Benjamin Brown of Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) discusses his own experience as a patient with cancer and how consensus around pharmacogenomic practices can improve the lives of patients.

New products will expand existing microbiology offerings and integrate new contamination control strategies.

In this interview for World Standards Week, Nakia Eldridge, PharmD, MPH, of US Pharmacopeia (USP), discusses USP's key achievements in 2024, while outlining the organization's 2025 goals.

The United States Pharmacopeia (USP) offers the industry’s most comprehensive auditing and testing program for dietary supplements with its USP Verified Mark.

Fouad Atouf, senior vice president of global biologics at US Pharmacopeia, discusses how established quality standards, drawing from the realm of small molecule drugs and evolving to meet the complexities of biologics, play a pivotal role in fostering trust.

Fouad Atouf, senior vice president of global biologics at US Pharmacopeia, discusses the importance of robust quality standards in addressing concerns regarding biosimilar safety and efficacy.

Naiffer Romero, MSc, MPH, discusses his work at U.S. Pharmacopeia to regulate nitrosamine impurities and ensure medication quality.

Following this year’s Match Day on March 15, pharmacists at US Pharmacopeia (USP) explain some of the opportunities student pharmacists can pursue outside of the traditional pharmacy career model.

Farah Towfic, PharmD, MBA, RPh, director, CEO Operations, US Pharmacopeia, discusses some of the primary topics impacting pharmacists’ delivery of care and quality this year.

USP executive notes importance of including different voices, perspectives for expansion of quality medicine.

Brian Serumaga, PhD, of US Pharmacopeia (USP) discusses the revisions to compounding chapters <795> and <797> and the resources available to help pharmacists update their practices.

A compliance officer role represents an exciting new challenge to ensure safe handling in compliance with United States Pharmacopeia.

This World Standards Week, Carrie Harney, JD, vice president, US Government and Regulatory Affairs at US Pharmacopeia (USP), explains how pharmacists contribute to USP’s standards setting process.

Farah Towfic, PharmD, MBA, RPh, director, CEO Operations, US Pharmacopeia, details some of the moments that led her to the pharmacy field and the important role that mentorship played in that process.

Desmond Hunt, PhD, senior principal scientist at US Pharmacopeia (USP), discusses the standards and resources that USP has recently published or is looking at now on the subject of pharmacy in transit.

Amy Cadwallader, PhD, director of Regulatory and Public Policy Development at US Pharmacopeia (USP), discusses how medicine quality and the medicines supply chain can affect antimicrobial resistance (AMR).

Nakia Eldridge, PharmD, MBA, director of health care quality, safety, and information at US Pharmacopeia (USP), discusses points of note regarding USP’s work in setting and supporting public quality standards.

Nicole Palmer, senior manager of Volunteer Engagement at US Pharmacopeia (USP), and Michelle Then, PharmD, MBA, member of the USP Healthcare Safety and Quality Expert Committee, discuss the benefits of being a volunteer at USP and the opportunities for students and early career pharmacists.

USP 800 was a necessary step to maximize safety, but it also recommended many institutions reevaluate their facilities, equipment, processes, and staffing capacity, potentially costing millions of dollars.

Vimala Raghavendran, MBA, head of the Pharmaceutical Supply Chain Center at US Pharmacopeia (USP), explains how pharmacists can get involved in USP’s Medicine Supply Vulnerability Insights Series assessing global pharmaceutical supply chain vulnerabilities.

Diane McCarthy, director of biologics pipeline development at US Pharmacopeia (USP), discusses USP’s development of mRNA quality guidelines to help companies and regulators bring innovative medicines to market faster.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses how building resilience in the medicine supply chain will help bolster preparedness for what may arise during the COVID-19 pandemic and beyond.